These findings demonstrate that combination therapy with anti-CTLA-4 antibody, anti-PD-1 antibody, and DT can inhibit Tregs, activate lymphocytes, and promote immune responses in breast cancer model mice (67). Here, PDCD1 is linked to breast carcinoma.